Edition:
India

Protagonist Therapeutics Inc (PTGX.OQ)

PTGX.OQ on NASDAQ Stock Exchange Global Market

6.85USD
22 Jun 2018
Change (% chg)

$-0.01 (-0.15%)
Prev Close
$6.86
Open
$6.87
Day's High
$6.98
Day's Low
$6.72
Volume
926,387
Avg. Vol
74,948
52-wk High
$23.68
52-wk Low
$5.92

Chart for

About

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing... (more)

Overall

Beta: --
Market Cap(Mil.): $317.10
Shares Outstanding(Mil.): 16.90
Dividend: --
Yield (%): --

Financials

BRIEF-Protagonist Therapeutics Reports Q1 Net Loss Per Share $0.36

* PROTAGONIST THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

10 May 2018

BRIEF-Protagonist Therapeutics Discontinues Phase 2B Propel Trial Of PTG-100

* PROTAGONIST THERAPEUTICS DISCONTINUES PHASE 2B PROPEL TRIAL OF PTG-100 FOR THE TREATMENT OF ULCERATIVE COLITIS FOLLOWING INTERIM ANALYSIS

26 Mar 2018

BRIEF-Protagonist Therapeutics Q4 Loss Per Share $0.15

* PROTAGONIST THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

08 Mar 2018

BRIEF-FDA Grants Orphan Drug Designation For Protagonist Therapeutics' PTG-300

* FDA GRANTS ORPHAN DRUG DESIGNATION FOR PROTAGONIST THERAPEUTICS' PTG-300 FOR THE TREATMENT OF BETA-THALASSEMIA Source text for Eikon: Further company coverage:

07 Mar 2018

BRIEF-Protagonist Therapeutics Granted Two New US Patents For Peptide Drug Candidates PTG-100 And PTG-300

* PROTAGONIST THERAPEUTICS GRANTED TWO NEW US PATENTS FOR PEPTIDE DRUG CANDIDATES PTG-100 AND PTG-300 Source text for Eikon: Further company coverage:

04 Jan 2018

Earnings vs. Estimates